Diabetes management is a critical aspect of life for millions of people worldwide. Traditional glucose monitoring methods, which involve frequent finger pricks, can be cumbersome and intrusive. Continuous glucose monitoring (CGM) devices offer an alternative by providing automatic tracking of glucose levels through devices worn on the body. However, these devices have their own set of limitations, such as lag time and the need for frequent sensor replacements.
Glucotrack, Inc. aims to address these challenges with its innovative Continuous Blood Glucose Monitor (CBGM). Unlike other CGM devices that measure interstitial glucose, Glucotrack's CBGM measures glucose directly in the blood, eliminating the lag time associated with subcutaneous sensors. This real-time monitoring capability offers a more accurate and less burdensome way to manage diabetes.
Current CGM devices, like those from DexCom Inc. and Abbott Laboratories, require sensors that need to be reapplied every 10 to 15 days and measure glucose from interstitial fluids. These sensors can also cause skin irritation and may fall off during physical activities. Eversense, developed by Senseonics Holdings Inc., offers a longer sensor life of up to 180 days but still measures interstitial glucose and requires an external transmitter.
Glucotrack's CBGM stands out by offering an implantable sensor that can last up to three years, significantly reducing the need for frequent replacements. This device also eliminates the need for an on-body wearable, providing increased discretion and comfort for users. The company claims that its device requires minimal calibration, making it easier to use compared to existing CGM systems.
Recent preclinical studies support Glucotrack's claims. The company reported a Mean Absolute Relative Difference (MARD) of 4.7% at day 90 in its latest 90-day preclinical study, a key metric indicating high accuracy in glucose monitoring. This study included a larger number of animal subjects and a longer duration than the initial 60-day study, further validating the device's sustained accuracy and performance.
Glucotrack presented this data at the 84th Scientific Sessions of the American Diabetes Association (ADA) and the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference. These presentations highlighted the device's potential acceptability and effectiveness in a larger population of people with diabetes.
Paul Goode, Ph.D., president and CEO of Glucotrack, stated, "Our CBGM's ability to continuously measure blood glucose for three years with accuracy, minimal calibration and without a wearable represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution."
As the global diabetes population is projected to reach 643 million by 2030 and 783 million by 2045, the need for effective and user-friendly glucose monitoring solutions is more critical than ever. Glucotrack's CBGM could be a game-changer, offering a more convenient, accurate, and less intrusive way to manage diabetes. If preclinical results are any indication, this technology could profoundly impact the lives of millions, making diabetes management more manageable and less burdensome.
